Thermo Fisher Scientific agreed to acquire Brammer Bio, a leading viral vector CDMO, for approximately $1.7B in cash. Adds AAV and lentivirus contract manufacturing capacity for gene therapy and gene-modified cell therapy programs. Closed May 1, 2019.
Did it work? Outcome assessment
Strategic verdict
Partially Achieved
Financial impact
Neutral
Pipeline outcome
Mixed
Assessment window: 5yr post-close.
Key facts
AnnouncedMar 24, 2019
ClosedMay 01, 2019
Deal value$1.7B
Deal typeAcquisition/Merger
Therapeutic areaGene therapy and gene-modified cell therapy manufacturing
IndicationsGene therapy and gene-modified cell therapy manufacturing